Agingreprograms IL-5 signaling in eosinophils toward ERK‑biased pro‑fibrotic activation, driving muscle ECM deposition and impairing regeneration

Prof. Mara Hayashi (PhD)· Mar 26, 2026

Mechanism: Proposed pathway in "Agingreprograms IL-5 signaling in eosinophils toward ERK‑biased pro‑fibrotic activation, driving muscle ECM deposition and impairing regeneration" links the intervention to the biological effect. Readout: Expected marker shifts are visualized with clear directional changes.

With age, IL-5 signaling in tissue-resident eosinophils shifts from a STAT5‑dominant regime that supports fibro/adipogenic progenitor (FAP) proliferation and IL-4‑mediated regeneration to an ERK‑biased regime that promotes TGF‑β‑driven fibroblast activation and extracellular matrix (ECM) accumulation in skeletal muscle. This signaling rewiring converts eosinophils from regenerative helpers into covert pro‑fibrotic contributors, linking eosinophil dysfunction to age-related sarcopenia and impaired muscle repair.

Mechanistic Rationale

Baseline IL-5 actions: In young muscle, IL-5 engages its receptor (IL-5Rα) to activate JAK2‑STAT5, Ras‑ERK, PI3K/AKT, and p38 MAPK pathways, promoting eosinophil survival, migration, and IL-4 secretion that stimulates FAP proliferation while blocking adipogenic differentiation [2][3]. STAT5 signaling also suppresses TGF‑β/SMAD2 transcriptional programs, limiting pro‑fibrotic output.
Age‑related signaling bias: Aging alters Gαi1/3‑mediated IL-5Rα endocytosis and downstream adaptor usage, favoring sustained ERK phosphorylation over STAT5 activation, as observed in neutrophils where JAK2 modulation reshapes immune responses with age [8]. ERK bias enhances eosinophil expression of TGF‑β receptors and SMAD2 phosphorylation, driving collagen (COL4A6) and MMP2 production that remodels the muscle ECM toward a stiff, non‑permissive niche [2].
Consequences for FAPs: Elevated TGF‑β from eosinophils pushes FAPs toward adipogenic and fibrotic fates, reducing their regenerative proliferation and increasing scar‑like matrix deposition. Simultaneously, diminished eosinophil-derived IL‑4 weakens the pro‑regenerative cue that normally counteracts FAP adipogenesis [1].
Systemic amplification: Age‑associated eosinophil loss in adipose tissue raises circulating CCL11, which further skews eosinophil recruitment toward inflammatory sites and exacerbates the ERK‑biased phenotype via autocrine IL‑5 loops [4].

Predictions & Experimental Design

Signaling profile: In eosinophils isolated from young vs. aged injured mouse muscle, phospho‑STAT5 will be significantly reduced while phospho‑ERK1/2 will be elevated in aged cells after IL‑5 stimulation (Western blot or flow cytometry).
Genetic test: Eosinophil‑specific deletion of Gαi1/3 (using Siglec‑F‑Cre) in aged mice will restore STAT5 bias, decrease eosinophil‑derived TGF‑β/SMAD2 activity, and reduce collagen deposition in muscle after cardiotoxin injury.
Pharmacological test: Acute treatment with a selective ERK pathway inhibitor (e.g., SCH772984) administered to aged injured mice will mimic the Gαi1/3 knockout phenotype—lower fibrosis, higher FAP proliferation, and improved muscle force recovery—without affecting eosinophil numbers.
Rescue test: Adoptive transfer of young eosinophils (WT) into aged mice will not improve regeneration unless the ERK bias is pharmacologically blocked, indicating that the functional defect is intrinsic to the eosinophil signaling state rather than mere cell number.

Potential Outcomes & Interpretation

If predictions hold: Data would support the hypothesis that aging reprograms IL-5 signaling in eosinophils toward an ERK‑driven pro‑fibrotic mode, directly linking eosinophil intrinsic signaling to muscle ECM maladysregeneration and sarcopenia.
If STAT5 remains unchanged but ERK rises: Suggests a parallel pathway where ERK activation overrides STAT5‑mediated repression of TGF‑β, still supporting the core idea of signaling bias.
If eosinophil-specific Gαi1/3 deletion fails to alter fibrosis: Implies that other age‑altered receptors or cytokine milieus dominate eosinophil reprogramming, prompting investigation of IL‑33/TST2 or TNF pathways.
If ERK inhibition rescues regeneration without altering eosinophil numbers: Highlights that eosinophil effector function, not mere infiltration, is the therapeutic target.

Overall, this hypothesis provides a falsifiable, mechanistic bridge between eosinophil biology, IL‑5 signaling dynamics, and age‑related muscle frailty, offering clear experimental avenues to test whether re‑balancing eosinophil signaling can restore regenerative capacity in aged muscle.

Mechanistic Rationale

Baseline IL-5 actions: In young muscle, IL-5 engages its receptor (IL-5Rα) to activate JAK2‑STAT5, Ras‑ERK, PI3K/AKT, and p38 MAPK pathways, promoting eosinophil survival, migration, and IL-4 secretion that stimulates FAP proliferation while blocking adipogenic differentiation [2][3]. STAT5 signaling also suppresses TGF‑β/SMAD2 transcriptional programs, limiting pro‑fibrotic output.

Age‑related signaling bias: Aging alters Gαi1/3‑mediated IL-5Rα endocytosis and downstream adaptor usage, favoring sustained ERK phosphorylation over STAT5 activation, as observed in neutrophils where JAK2 modulation reshapes immune responses with age [8]. ERK bias enhances eosinophil expression of TGF‑β receptors and SMAD2 phosphorylation, driving collagen (COL4A6) and MMP2 production that remodels the muscle ECM toward a stiff, non‑permissive niche [2].

Consequences for FAPs: Elevated TGF‑β from eosinophils pushes FAPs toward adipogenic and fibrotic fates, reducing their regenerative proliferation and increasing scar‑like matrix deposition. Simultaneously, diminished eosinophil-derived IL‑4 weakens the pro‑regenerative cue that normally counteracts FAP adipogenesis [1].

Systemic amplification: Age‑associated eosinophil loss in adipose tissue raises circulating CCL11, which further skews eosinophil recruitment toward inflammatory sites and exacerbates the ERK‑biased phenotype via autocrine IL‑5 loops [4].

Predictions & Experimental Design

Signaling profile: In eosinophils isolated from young vs. aged injured mouse muscle, phospho‑STAT5 will be significantly reduced while phospho‑ERK1/2 will be elevated in aged cells after IL‑5 stimulation (Western blot or flow cytometry).

Genetic test: Eosinophil‑specific deletion of Gαi1/3 (using Siglec‑F‑Cre) in aged mice will restore STAT5 bias, decrease eosinophil‑derived TGF‑β/SMAD2 activity, and reduce collagen deposition in muscle after cardiotoxin injury.

Pharmacological test: Acute treatment with a selective ERK pathway inhibitor (e.g., SCH772984) administered to aged injured mice will mimic the Gαi1/3 knockout phenotype—lower fibrosis, higher FAP proliferation, and improved muscle force recovery—without affecting eosinophil numbers.

Rescue test: Adoptive transfer of young eosinophils (WT) into aged mice will not improve regeneration unless the ERK bias is pharmacologically blocked, indicating that the functional defect is intrinsic to the eosinophil signaling state rather than mere cell number.

Potential Outcomes & Interpretation

If predictions hold: Data would support the hypothesis that aging reprograms IL-5 signaling in eosinophils toward an ERK‑driven pro‑fibrotic mode, directly linking eosinophil intrinsic signaling to muscle ECM maladysregeneration and sarcopenia.

If STAT5 remains unchanged but ERK rises: Suggests a parallel pathway where ERK activation overrides STAT5‑mediated repression of TGF‑β, still supporting the core idea of signaling bias.

If eosinophil-specific Gαi1/3 deletion fails to alter fibrosis: Implies that other age‑altered receptors or cytokine milieus dominate eosinophil reprogramming, prompting investigation of IL‑33/TST2 or TNF pathways.

If ERK inhibition rescues regeneration without altering eosinophil numbers: Highlights that eosinophil effector function, not mere infiltration, is the therapeutic target.